Skip to main content
Log in

Significance of Intramural Metastasis in Patients with Esophageal Squamous Cell Carcinoma: An Indicator of Aggressive Cancer Behavior

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Intramural metastasis (IM) is occasionally noted in patients with esophageal squamous cell carcinoma (ESCC). However, few recent studies have investigated the clinicopathological characteristics of IM and its survival impact. The present study aimed to clarify the clinicopathological and prognostic significance of IM in patients with ESCC.

Methods

We retrospectively examined 918 consecutive patients who underwent curative intent esophagectomy for ESCC. IM was defined as a pathologically confirmed metastatic lesion, which was clearly separate from the primary tumor and located within the esophageal or gastric wall. The clinicopathological characteristics and survival impact of IM were evaluated. A propensity score-matched analysis was performed to further elucidate the prognostic impact of IM.

Results

Among 918 patients, 46 (5.0%) had IM. Advanced tumors were significantly more frequent in patients with IM than in those without IM. The curative resection rate was lower in patients with IM (P = 0.001). Overall survival (OS) and disease-specific survival (DSS) were worse in patients with IM (both P < 0.001). In multivariate Cox proportional hazard analysis, IM presence was an independent poor prognostic indicator for OS and DSS (both P < 0.001). After propensity score matching, advanced tumors according to pathological N stage and lymphatic invasion were more frequent in patients with IM (P = 0.015 and 0.004, respectively). Additionally, OS and DSS were different between patients with and those without IM (both P = 0.002).

Conclusions

IM from ESCC is a local indicator of lymphatic invasion and advanced cancer, as well as an independent factor for poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Takubo K, Sasajima K, Yamashita K et al (1990) Prognostic significance of intramural metastasis in patients with esophageal carcinoma. Cancer 65:1816–1819

    Article  CAS  PubMed  Google Scholar 

  2. Kato H, Tachimori Y, Watanabe H et al (1992) Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer 50:49–52

    Article  CAS  PubMed  Google Scholar 

  3. Kuwano H, Watanabe M, Sadanaga N et al (1994) Univariate and multivariate analyses of the prognostic significance of discontinuous intramural metastasis in patients with esophageal cancer. J Surg Oncol 57:17–21

    Article  CAS  PubMed  Google Scholar 

  4. Nishimaki T, Suzuki T, Tanaka Y et al (1996) Intramural metastases from thoracic esophageal cancer: local indicators of advanced disease. World J Surg 20:32–37. https://doi.org/10.1007/s002689900006

    Article  CAS  PubMed  Google Scholar 

  5. Hokamura N, Kato H, Tachimori Y et al (2000) Preoperative chemotherapy for esophageal carcinoma with intramural metastasis. J Surg Oncol 75:117–121

    Article  CAS  PubMed  Google Scholar 

  6. Yuasa N, Miyake H, Yamada T et al (2004) Prognostic significance of the location of intramural metastasis in patients with esophageal squamous cell carcinoma. Langenbecks Arch Surg 389:122–127

    Article  PubMed  Google Scholar 

  7. Hashimoto T, Arai K, Yamashita Y et al (2013) Characteristics of intramural metastasis in gastric cancer. Gastric Cancer 16:537–542

    Article  CAS  PubMed  Google Scholar 

  8. Moon DH, Jeon JH, Yang HC et al (2018) Intramural metastasis as a risk factor for recurrence in esophageal squamous cell carcinoma. Ann Thorac Surg 106:249–256

    Article  PubMed  Google Scholar 

  9. Kuwano H, Nishimura Y, Oyama T et al (2015) Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus 12:1–30

    Article  PubMed  Google Scholar 

  10. Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74

    Article  PubMed  Google Scholar 

  11. Kuwano H, Nishimura Y, Ohtsu A et al (2008) Guidelines for diagnosis and treatment of carcinoma of the esophagus: April 2007 edition: part I edited by the Japan Esoplageal Society. Esophagus 5:61–73

    Article  Google Scholar 

  12. Kuwano H, Nishimura Y, Ohtsu A et al (2008) Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition: part II edited by the Japan Esophageai Society. Esophagus 5:117–132

    Article  Google Scholar 

  13. International Union Against Cancer (2017) In: Brierley JDGM, Wittekind C (eds) TNM classification of malignant tumors, 8th edn. Wiley, Oxford

    Google Scholar 

  14. Watson W (1933) Carcinoma of the esophagus. Surg Gynecol Obstet 56:884–897

    Google Scholar 

  15. Okamura A, Watanabe M, Mine S et al (2017) Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Dis Esophagus 30:1–8

    Article  CAS  PubMed  Google Scholar 

  16. Hara H, Tahara M, Daiko H et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455–1460

    Article  CAS  PubMed  Google Scholar 

  17. Watanabe M, Baba Y, Yoshida N et al (2014) Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol 21:2838–2844

    Article  PubMed  Google Scholar 

  18. Shiraishi O, Yamasaki M, Makino T et al (2017) Feasibility of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus adriamycin, cisplatin, and 5-fluorouracil for resectable advanced esophageal cancer. Oncology 92:101–108

    Article  CAS  PubMed  Google Scholar 

  19. Yang H, Liu H, Chen Y et al (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 36:2796–2803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masayuki Watanabe.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamura, A., Watanabe, M., Kozuki, R. et al. Significance of Intramural Metastasis in Patients with Esophageal Squamous Cell Carcinoma: An Indicator of Aggressive Cancer Behavior. World J Surg 43, 1997–2005 (2019). https://doi.org/10.1007/s00268-019-05004-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-019-05004-z

Navigation